Compartilhar
Informação da revista
Vol. 94. Núm. 1.
Páginas 99-101 (1 janeiro 2019)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
5117
Vol. 94. Núm. 1.
Páginas 99-101 (1 janeiro 2019)
Open Access
Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder*
Visitas
5117
Flávia de Oliveira Valentim1, Cristiano Claudino Oliveira2,3, Hélio Amante Miot1
1 Department of Dermatology, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu (SP), Brazil.
2 Department of Pathology, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu (SP), Brazil
3 Department of Pathological Anatomy, Hospital São Luiz/D’Or, São Paulo (SP), Brazil
Este item recebeu

Under a Creative Commons license
Informação do artigo
Resume
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (3)
Mostrar maisMostrar menos
Tabelas (1)
Chart 1. Classification of primary cutaneous T and NK cell lymphoproliferative disorders
Abstract:

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a rare disease, with an indolent evolution and benign course. The classic presentation is a solitary nodule on the face or trunk. The disorder’s rarity and clinical and histopathological characteristics, can make the diagnosis difficult. We present the case of a 36-year-old Caucasian woman with a purplish erythematous nodule, hardened, shiny, asymptomatic, on the left nasal ala, which had grown progressively for 45 days. Histopathological examination and immunohistochemistry panel demonstrated alterations consistent with primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. There was complete remission of the condition within 60 days of treatment with potent occlusive corticosteroids.

Keywords:
Lymphoma
Lymphoproliferative disorders
Pseudolymphoma
Texto Completo
Case Report

The patient was a 36-year-old female, Caucasian, schoolteacher, who reported a single purplish erythematous nodule with a firm consistency and shiny surface, with telangiectasias, clear contour, non-pruritic, located on the left nasal ala, approximately 1.5 cm in diameter, which had grown progressively for 45 days (Figure 1). No lymphadenopathy, visceromegaly, or other associated signs were identified. Histopathological examination showed atypical and diffuse lymphocytic infiltrate in the dermis, reaching the subcutaneous layer and involving the perivascular tissue. Lymphocytes were small to intermediate in size (Figure 2). Immunohistochemistry revealed a predominance of CD3+ T lymphocytes, with CD4+ immunopositivity (Figure 3). The cell proliferation index (Ki-67) was estimated at 10-15%, and there were rare CD30+ cells. Populations of plasma cells, histiocytes, and CD8+ T lymphocytes were observed in the background. Further tests such as CT scan, biochemical tests, blood count, lactate dehydrogenase, and β2-microglobulin levels were normal.

Figure 1.

Purplish erythematous nodule with firm shiny surface on the left nasal ala

A - lateral view

B - Lower view

(0.2MB).
Figure 2.

A - Histological skin section of dense lymphocytic infiltrate in the dermis (Hematoxylin & eosin, x50)

B - Histological skin section demonstrating the nuclear pattern of the lymphocytes in the lesion: small to medium-sized nuclei, predominantly regular karyotheca, hyperchromasia and perivascular and periadnexal arrangement, with no foci of epidermotropism (Hematoxylin & eosin, x400)

(0.35MB).
Figure 3.

A - Area with perivascular dermal lymphocytic infiltrate (Immunohistochemistry, CD4, x400). Prevalence of CD4 T lymphocytes

B - Area with perivascular dermal lymphocytic infiltrate. CD4 T lymphocytes predominate over CD8 T lymphocytes (Immunohistochemistry, CD8, x400)

(0.45MB).
Discussion

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, previously called CD4+ small/medium pleomorphic T cell lymphoma, is a rare disease with indolent and insidious evolution, classically presenting as a solitary nodule on the face, neck, or trunk.1 Cases have been described in patients with some degree of immune compromise such as transplanted patients and those in use of immunobiologicals.2,3

Despite the benign and favorable course of this disease, both the diagnosis and therapeutic approach remain challenging for dermatologists and pathologists.4 In 2017, the World Health Organization reviewed the classification of lymphomas and reclassified this primary cutaneous lymphoma (2005) as a lymphoproliferative disease (2017) (Chart 1).5,6

Chart 1.

Classification of primary cutaneous T and NK cell lymphoproliferative disorders

Mycosis fungoides 
Sézary syndrome 
Primary cutaneous CD30+ T-cell lymphoproliferative disorders 
Lymphomatoid papulosis 
Primary cutaneous anaplastic large cell lymphoma 
Peripheral primary cutaneous T-cell lymphoma and lymphoproliferative disorders, rare cases 
Primary cutaneous gamma/delta T-cell lymphoma 
Primary cutaneous CD+ aggressive epidermotropic cytotoxic T-cell lymphoma 
Primary cutaneous acral CD8+ T-cell lymphoma*
Primary cutaneous CD+ small/medium sized T-cell lymphoproliferative disorder* 
Subcutaneous panniculitis-like T-cell lymphoma 
Extranodal NK/T-cell lymphoma, nasal type 

Source: Swerdlow SH, et al, 2017.5

*

Changes from 2008 classification

The distinction between cutaneous T-cell lymphoproliferative disorder and its differential diagnoses is extremely important, modifying the prognosis and treatment approach, particularly in relation to primary cutaneous CD8+ epidermotropic cytotoxic T-cell lymphoma, which has an aggressive clinical course and presents with morphological necrosis and ulceration. Other differential diagnoses include: mycosis fungoides and subtypes, which can be distinguished from each other based on clinical history and rapid evolution; primary cutaneous acral CD8+ T-cell lymphoma, which may overlap in its topography and clinical presentation but with a different immunophenotype and better prognosis; and primary cutaneous gamma/delta T-cell lymphoma, with highly aggressive clinical and morphological features.1,4,7

Markers of poor evolution and worse prognosis in cutaneous T-cell lymphoproliferative disorders include: disseminated lesions, rapid growth, and presence of more than 30% of large pleomorphic CD30+ T lymphocytes and/or high rates of cell proliferation, similar to that observed in high-grade lymphomas.1,7

The medical literature includes case reports showing efficient treatments, such as oral doxycycline, corticosteroids (topical, intralesional, and/or oral), surgical excision, and radiotherapy. However, there is no consensus on the best therapeutic approach for these cases.1,5, 7-10

The proposed treatment for this patient was occlusive fluocinolone (in patches), leading to the complete remission of the lesion within 60 days and no relapse in 90 days of follow-up. Potent corticosteroids have a lympholytic effect, promoting rapid involution of the infiltrate in localized forms, with low cost and high tolerability.

Financial support: None

Conflict of interest: None

References
[1.]
E. James, JG Sokhn, J.F. Gibson, K. Carlson, A. Subtil, M. Girardi, et al.
CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature.
Leuk Lymphoma, 56 (2015), pp. 951-957
[2.]
B. Shakerian, N. Razavi, M.H. Mandegar.
Primary Cutaneous CD4-Positive Small/ Medium-Sized Pleomorphic T-Cell Lymphoma Following Heart Transplantation.
Int J Organ Transplant Med, 8 (2017), pp. 168-169
[3.]
H. Ma, S. Qiu, R. Lu, P. Feng, C. Lu.
Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma.
An Bras Dermatol, 91 (2016), pp. 368-371
[4.]
S. Alberti-Violetti, CA. Torres-Cabala, R. Talpur, L. Corti, D. Fanoni, L. Venegoni, et al.
Clinicopathological and molecular study of primary cutaneous CD4+ small/ medium-sized pleomorphic T-cell lymphoma.
J Cutan Pathol, 43 (2016), pp. 1121-1130
[5.]
S.H. Swerdlow, E. Campo, NL. Harris, ES. Jaffe, SA Pileri, H Stein, et al.
WHO Classification of tumors of Haematopoietic and Lymphoid Tissues.
4th, IARC, (2015),
[6.]
S.H. Swerdlow, E. Campo, SA. Pileri, NL. Harris, H. Stein, R. Siebert, et al.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Blood, 127 (2016), pp. 2375-2390
[7.]
C.L. Baum, B.K. Link, V.T. Neppalli, B.L. Swick, V. Liu.
Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature.
J Am Acad Dermatol, 65 (2011), pp. 739-748
[8.]
F. Toberer, W. Hartschuh, E. Hadaschik.
Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma: temporary remission by oral doxycycline.
JAMA Dermatol, 149 (2013), pp. 956-959
[9.]
B.H. Keeling, A.CP. Gavino, J. Admirand, A.C. Soldano.
Primary cutaneous CD4- positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature.
J Cutan Pathol, 44 (2017), pp. 944-947
[10.]
M. Maurelli, C. Colato, P. Gisondi, G. Girolomoni.
Primary Cutaneous CD4(+) Small/ Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series.
J Cutan Med Surg, 21 (2017), pp. 502-506

Work conducted at the Departments of Dermatology and Pathology, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu (SP), Brazil

Copyright © 2019. Anais Brasileiros de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.